[CERS] Cerus Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.66 Change: 0.26 (5.91%)
Ext. hours: Change: 0 (0%)

chart CERS

Refresh chart

Strongest Trends Summary For CERS

CERS is in the medium-term down -14% in 1 month. In the long-term up 143% in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company in Europe, the Commonwealth of Independent States, and the Middle East. The company develops and commercializes the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company?s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for tran

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.63 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -10.57% Sales Growth - Q/Q-19.77% P/E-3.54
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-33.51% ROE-43.65% ROI-39.88%
Current Ratio5.99 Quick Ratio5.29 Long Term Debt/Equity0.08 Debt Ratio0.21
Gross Margin40% Operating Margin-137.01% Net Profit Margin-132.42% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities76.5 M Cash From Investing Activities-65.59 M Cash From Operating Activities-15.75 M Gross Profit2.98 M
Net Profit-9.46 M Operating Profit-14.37 M Total Assets143.22 M Total Current Assets136.42 M
Total Current Liabilities22.76 M Total Debt9.88 M Total Liabilities33.29 M Total Revenue7.69 M
Technical Data
High 52 week7.78 Low 52 week4.89 Last close5.47 Last change-0.36%
RSI34.78 Average true range0.32 Beta0.96 Volume739.37 K
Simple moving average 20 days-7.47% Simple moving average 50 days-10.71% Simple moving average 200 days-12.25%
Performance Data
Performance Week-1.26% Performance Month-5.69% Performance Quart-15.46% Performance Half3.21%
Performance Year-14.66% Performance Year-to-date7.89% Volatility daily3.57% Volatility weekly7.99%
Volatility monthly16.38% Volatility yearly56.73% Relative Volume436.07% Average Volume832.48 K
New High New Low

News

2019-06-24 18:00:00 | Cerus Corporation Announces Presentations Highlighting INTERCEPT Blood System at the 29th Regional Congress of the ISBT

2019-06-04 14:16:08 | How Cerus Corporation NASDAQ:CERS Can Impact Your Portfolio Volatility

2019-06-03 08:30:00 | Cerus Corporation Announces New Corporate Brand and Global Headquarters

2019-05-14 08:44:00 | Cerus’ INTERCEPT Blood System Provides Alternative to Year-Round Babesia Testing in Latest FDA Guidance Document

2019-05-08 17:39:10 | Edited Transcript of CERS earnings conference call or presentation 7-May-19 8:30pm GMT

2019-05-07 20:23:52 | Cerus Corporation CERS Q1 2019 Earnings Call Transcript

2019-05-07 19:25:11 | Cerus CERS Reports Q1 Loss, Tops Revenue Estimates

2019-05-07 18:18:46 | Cerus: 1Q Earnings Snapshot

2019-05-07 16:05:00 | Cerus Corporation Announces Record First Quarter 2019 Results

2019-05-07 10:53:45 | Here’s What Hedge Funds Think About Cerus Corporation CERS

2019-04-30 10:32:02 | Analysts Estimate Cerus CERS to Report a Decline in Earnings: What to Look Out for

2019-04-25 08:30:00 | Cerus Corporation to Release First Quarter 2019 Results on May 7, 2019

2019-04-24 11:48:58 | Cerus Corporation NASDAQ:CERS Insiders Have Been Selling

2019-04-01 16:05:00 | Cerus Corporation Strengthens Balance Sheet with an Expandable Debt Facility of up to $90 Million

2019-03-05 16:15:00 | Cerus Corporation Announces Appointment of Jami Nachtsheim to Board of Directors

2019-02-27 16:09:11 | Edited Transcript of CERS earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-26 23:02:34 | Cerus Corporation CERS Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:02:00 | Cerus Corporation Announces Record Fourth Quarter and Full Year 2018 Results

2019-02-22 08:30:00 | Cerus to Participate In Upcoming Investor Conferences

2019-02-21 11:20:20 | How Much Of Cerus Corporation NASDAQ:CERS Do Institutions Own?

2019-02-14 07:20:00 | Consolidated Research: 2019 Summary Expectations for Varonis, Dolby Laboratories, Alder BioPharmaceuticals, Retail Properties of America, Cerus, and Motorcar Parts of America — Fundamental Analysis, Key Performance Indications

2019-02-13 08:30:00 | Cerus to Release Fourth Quarter and Full Year 2018 Results on February 26, 2019

2019-01-16 11:00:17 | How Should Investors React To Cerus Corporation’s NASDAQ:CERS CEO Pay?

2019-01-07 08:30:00 | Cerus Announces Preliminary Fourth Quarter and Full Year 2018 Product Revenue

2019-01-04 08:30:00 | William Moore Appointed as Cerus Corporation’s Senior Vice President of Manufacturing Operations and Supply Chain

2018-12-19 08:30:00 | Cerus Announces First Patient Enrolled in the Phase 3 ReCePI Study

2018-12-18 08:30:00 | Cerus Completes CE Mark Submission for INTERCEPT Red Blood Cells

2018-12-18 02:14:47 | Do Hedge Funds Love Cerus Corporation CERS?

2018-12-17 10:39:41 | What Investors Should Know About Cerus Corporation’s NASDAQ:CERS Financial Strength

2018-12-10 08:30:00 | American Red Cross Receives Biologics License Application Approval For INTERCEPT Platelets

2018-12-04 17:00:00 | Cerus Supports FDA’s Continuing Efforts to Enhance the Safety of the U.S. Platelet Supply

2018-11-15 10:48:02 | Does Cerus Corporation NASDAQ:CERS Have A Particularly Volatile Share Price?

2018-11-12 07:20:00 | Report: Developing Opportunities within Lexicon Pharmaceuticals, Cray, RCI Hospitality, Sanmina, Diamond Offshore Drilling, and Cerus — Future Expectations, Projections Moving into 2018

2018-11-09 08:30:00 | Cerus to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

2018-11-02 08:30:00 | Cerus to Present at the 2018 Stephens NY Investment Conference

2018-11-02 08:10:12 | Edited Transcript of CERS earnings conference call or presentation 1-Nov-18 8:15pm GMT

2018-11-01 17:25:35 | Cerus: 3Q Earnings Snapshot

2018-11-01 16:01:00 | Cerus Corporation Reports Third Quarter 2018 Results

2018-10-31 08:30:00 | Cerus Receives FDA Breakthrough Device Designation for Pathogen-Reduced Cryoprecipitate

2018-10-23 08:30:00 | Cerus to Release Third Quarter 2018 Results on November 1, 2018

2018-10-18 08:10:00 | Detailed Research: Economic Perspectives on Cerus, AdvanSix, Spark Therapeutics, Imperva, Central Garden & Pet, and Francesca's — What Drives Growth in Today's Competitive Landscape

2018-10-16 15:01:00 | Here's Why Cerus Corporation Stock Popped Today

2018-10-16 08:30:00 | Cerus to Provide Update to Development Programs and Outline Growth Strategy at 2018 Institutional Investor Meeting

2018-10-12 08:30:00 | Cerus Announces Schedule of Presentations at the 2018 AABB Annual Meeting

2018-10-11 08:30:00 | Dr. Laurence Corash Recognized With the Prestigious Dale A. Smith Memorial Award

2018-10-10 11:28:26 | Cerus Corporation’s NASDAQ:CERS Most Important Factor To Consider

2018-10-09 16:05:00 | Cerus Appoints Eric Bjerkholt to Board of Directors

2018-10-02 08:30:00 | Cerus to Host Institutional Investor Meeting

2018-09-26 08:30:00 | Cerus to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

2018-09-06 16:15:00 | Cerus Appoints Timothy L. Moore to Board of Directors